TY - JOUR
T1 - Self-Assembled Cyclic d,l-α-Peptides as Generic Conformational Inhibitors of the α-Synuclein Aggregation and Toxicity
T2 - In Vitro and Mechanistic Studies
AU - Chemerovski-Glikman, Marina
AU - Rozentur-Shkop, Eva
AU - Richman, Michal
AU - Grupi, Asaf
AU - Getler, Asaf
AU - Cohen, Haim Y.
AU - Shaked, Hadassa
AU - Wallin, Cecilia
AU - Wärmländer, Sebastian K.T.S.
AU - Haas, Elisha
AU - Gräslund, Astrid
AU - Chill, Jordan H.
AU - Rahimipour, Shai
N1 - Publisher Copyright:
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2016/9/26
Y1 - 2016/9/26
N2 - Many peptides and proteins with large sequences and structural differences self-assemble into disease-causing amyloids that share very similar biochemical and biophysical characteristics, which may contribute to their cross-interaction. Here, we demonstrate how the self-assembled, cyclic d,l-α-peptide CP-2, which has similar structural and functional properties to those of amyloids, acts as a generic inhibitor of the Parkinson′s disease associated α-synuclein (α-syn) aggregation to toxic oligomers by an „off-pathway“ mechanism. We show that CP-2 interacts with the N-terminal and the non-amyloid-β component region of α-syn, which are responsible for α-syn′s membrane intercalation and self-assembly, thus changing the overall conformation of α-syn. CP-2 also remodels α-syn fibrils to nontoxic amorphous species and permeates cells through endosomes/lysosomes to reduce the accumulation and toxicity of intracellular α-syn in neuronal cells overexpressing α-syn. Our studies suggest that targeting the common structural conformation of amyloids may be a promising approach for developing new therapeutics for amyloidogenic diseases.
AB - Many peptides and proteins with large sequences and structural differences self-assemble into disease-causing amyloids that share very similar biochemical and biophysical characteristics, which may contribute to their cross-interaction. Here, we demonstrate how the self-assembled, cyclic d,l-α-peptide CP-2, which has similar structural and functional properties to those of amyloids, acts as a generic inhibitor of the Parkinson′s disease associated α-synuclein (α-syn) aggregation to toxic oligomers by an „off-pathway“ mechanism. We show that CP-2 interacts with the N-terminal and the non-amyloid-β component region of α-syn, which are responsible for α-syn′s membrane intercalation and self-assembly, thus changing the overall conformation of α-syn. CP-2 also remodels α-syn fibrils to nontoxic amorphous species and permeates cells through endosomes/lysosomes to reduce the accumulation and toxicity of intracellular α-syn in neuronal cells overexpressing α-syn. Our studies suggest that targeting the common structural conformation of amyloids may be a promising approach for developing new therapeutics for amyloidogenic diseases.
KW - amyloids
KW - cyclic d,l-α-peptides
KW - inhibitors
KW - synucleinophathies
KW - α-synuclein
UR - http://www.scopus.com/inward/record.url?scp=84982217673&partnerID=8YFLogxK
U2 - 10.1002/chem.201601830
DO - 10.1002/chem.201601830
M3 - Article
C2 - 27539220
AN - SCOPUS:84982217673
SN - 0947-6539
VL - 22
SP - 14236
EP - 14246
JO - Chemistry - A European Journal
JF - Chemistry - A European Journal
IS - 40
ER -